Since Wallace Brigden first used the term 'cardiomyopathy' in 1952, this group of diseases has continued to attract the interest of clinicians, researchers, and importantly, patients. The past decade has seen a substantial accumulation of knowledge relating to various cardiomyopathies, which has partially lifted the mystery surrounding this topic.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
When signalling goes wrong: pathogenic variants in structural and signalling proteins causing cardiomyopathies
Journal of Muscle Research and Cell Motility Open Access 01 August 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cecchi, F., Tomberli, B. & Olivotto, I. Clinical and molecular classification of cardiomyopathies. Glob. Cardiol. Sci. Pract. 2012, 4 (2012).
Herman, D. S. et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619–628 (2012).
Golbus, J. R. et al. Population-based variation in cardiomyopathy genes. Circ. Cardiovasc. Genet. 5, 391–399 (2012).
Pan, S. et al. Cardiac structure and sarcomeric genes associated with cardiomyopathy exhibit marked intolerance of genetic variation. Circ. Cardiovasc. Genet. 5, 602–610 (2012).
Kalozoumi, G., Tzimas, C. & Sanoudou, D. The expanding role of epigenetics. Glob. Cardiol. Sci. Pract. 2012, 7 (2012).
Olivotto, I. et al. Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat. Rev. Cardiol. 6, 317–321 (2009).
Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J. Clin. Invest. 120, 3520–3529 (2010).
Gaendrarao, P. et al. Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS ONE 8, e59206 (2013).
Coppini, R. et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127, 575–584 (2013).
Jiang, J. et al. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 342, 111–114 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yacoub, M. Cardiomyopathy on the move. Nat Rev Cardiol 11, 628–629 (2014). https://doi.org/10.1038/nrcardio.2014.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.157
This article is cited by
-
Towards precision medicine in heart failure
Nature Reviews Cardiology (2021)
-
The p.Ala2430Val mutation in filamin C causes a "hypertrophic myofibrillar cardiomyopathy"
Journal of Muscle Research and Cell Motility (2021)
-
When signalling goes wrong: pathogenic variants in structural and signalling proteins causing cardiomyopathies
Journal of Muscle Research and Cell Motility (2017)